Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director
29 Septiembre 2021 - 3:00PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that the independent members of the Merck
Board of Directors have appointed Thomas H. Glocer as independent
lead director effective immediately.
Mr. Glocer has served on the Merck Board of Directors since
2007. He has extensive management, operational, technology and
international business expertise, including his history of
accomplishment and executive leadership while chief executive
officer and a director of Thomson Reuters Corporation. Mr. Glocer
also serves as independent lead director at Morgan Stanley.
“Since Tom joined our board in 2007, his expertise, counsel and
guidance have been invaluable to our company,” said Rob Davis,
chief executive officer and president, Merck. “Tom is a strategic,
insightful and accomplished corporate leader, and I look forward to
our continued collaboration and partnership as we continue to
deliver value to our stakeholders and ensure the short- and
long-term success of our company.”
About Merck
For over 130 years, Merck, known as MSD outside of the United
States and Canada, has been inventing for life, bringing forward
medicines and vaccines for many of the world’s most challenging
diseases in pursuit of our mission to save and improve lives. We
demonstrate our commitment to patients and population health by
increasing access to health care through far-reaching policies,
programs and partnerships. Today, Merck continues to be at the
forefront of research to prevent and treat diseases that threaten
people and animals – including cancer, infectious diseases such as
HIV and Ebola and emerging animal diseases – as we aspire to be the
premier research-intensive biopharmaceutical company in the world.
For more information, visit www.merck.com and connect with us on
Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210929005873/en/
Media Contacts: Patrick Ryan (973) 275-7075 Jackie Califano
(973) 296-6663
Investor Contacts: Peter Dannenbaum (908) 740-1037 Raychel
Kruper (908) 740-2107
Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024